¼¼°èÀÇ ÀüÀå ¿¢¼Ø ½ÃÄö½Ì ½ÃÀå º¸°í¼­(2025³â)
Whole Exome Sequencing Global Market Report 2025
»óǰÄÚµå : 1824319
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,469,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,350,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,232,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀüÀå ¿¢¼Ø ½ÃÄö½Ì ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ºñ¾àÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. 2029³â¿¡´Â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 21.3%¸¦ ³ªÅ¸³» 72¾ï 7,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº Á¾¾çÇп¡¼­ÀÇ ÀÀ¿ëÀÇ È®´ë, ÀÓ»óÁø´Ü¿¡¼­ÀÇ ÅëÇÕ, À¯ÀüÀÚ°Ë»ç ¼ö¿ä Áõ°¡, Àα¸À¯ÀüüÇп¡ ´ëÇÑ ´ëó, À¯ÀüÀÚ Ä¡·áÀÇ ÃâÇö¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ÀÓ»óÀû À¯¿ë¼ºÀÇ Çâ»ó°ú ä¿ë, ½ÃÄö½Ì ºñ¿ëÀÇ ÀúÇÏ, µ¥ÀÌÅÍ º¸¾È°ú ÇÁ¶óÀ̹ö½ÃÀÇ Áß½Ã, ÀüÀÚ ÀÇ·á ±â·Ï°úÀÇ ÅëÇÕ, ½Ì±Û ¼¿ ½ÃÄö½ÌÀÇ Áøº¸ µîÀÌ ÀÖ½À´Ï´Ù.

ÇâÈÄ 5³â°£ÀÇ ¼ºÀå·ü 21.3%¶ó°í ÇÏ´Â ¿¹ÃøÀº Àüȸ ¿¹ÃøÀ¸·ÎºÎÅÍ 0.1%ÀÇ ¼ÒÆøÀÇ °¨¼Ò¸¦ ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ÀÌ °¨¼Ò´Â ÁÖ·Î ¹Ì±¹°ú ´Ù¸¥ ±¹°¡ °£ÀÇ °ü¼¼ÀÇ ¿µÇâ ¶§¹®ÀÔ´Ï´Ù. ¹«¿ª ¸¶Âû·Î ÀÎÇØ Çѱ¹°ú À̽º¶ó¿¤¿¡¼­ °³¹ßµÈ Â÷¼¼´ë ½ÃÄö½Ì Ç÷§Æû ¹× ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼ÒÇÁÆ®¿þ¾îÀÇ °¡°ÝÀÌ »ó½ÂÇÏ¿© Èñ±ÍÁúȯÀÇ Áø´ÜÀÌ Áö¿¬µÇ°Å³ª À¯Àüü ÀÇ·á ÇÁ·Î±×·¥ÀÇ ºñ¿ëÀÌ »ó½ÂÇÏ¿© ¹Ì±¹ÀÇ À¯ÀüÀÚ Áø´Ü¿¡ ÁöÀåÀ» ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ »óÈ£°ü¼¼¿Í ¹«¿ªÀÇ ±äÀå°ú ÇѰè Áõ°¡·Î ÀÎÇÑ ¼¼°è°æÁ¦¿Í ¹«¿ª¿¡ ´ëÇÑ ¾Ç¿µÇâÀ¸·Î ÀÎÇØ ±× ¿µÇâÀÌ ´õ¿í ±¤¹üÀ§ÇØÁú °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

HIV(Àΰ£ ¸é¿ª°áÇÌ ¹ÙÀÌ·¯½º)ÀÇ À¯Çà Áõ°¡´Â ÇâÈÄ ÀüÀå ¿¢¼Ø ½ÃÄö½Ì ½ÃÀå ¼ºÀåÀ» À̲ø °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. HIV´Â ½ÅüÀÇ ¸é¿ª ü°è¸¦ °ø°ÝÇÏ´Â ¹ÙÀÌ·¯½ºÀÔ´Ï´Ù. ÀüÀå ¿¢¼Ø ½ÃÄö½Ì´Â HIVÀÇ ¸ÂÃãÇü Ä¡·á ¹× ¹é½Å °³¹ß¿¡ µµ¿òÀÌ µÇ´Â ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ À¯Àüü µ¥ÀÌÅ͸¦ Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 8¿ù ¹Ì±¹ Á¤ºÎ±â°üÀÎ ¸¶À̳ʸ®Æ¼ HIV/AIDS ±â±Ý(MHAF)Àº 2023³â ¼¼°è¿¡¼­ ¾à 3,990¸¸¸íÀÌ HIV¿¡ °¨¿°µÇ¾ú´Ù°í º¸°íÇßÀ¸¸ç, ±× ³»¿ªÀº ¼ºÀÎ 3,860¸¸¸í, ¾î¸°ÀÌ 140¸¸¸íÀ¸·Î ÀÌÀü¿¡ ºñÇØ Áõ°¡Çϰí ÀÖÀ½À» ³ªÅ¸³Â½À´Ï´Ù. ±× °á°ú HIVÀÇ À¯º´·ü »ó½ÂÀÌ ÀüÀå ¿¢¼Ø ½ÃÄö½Ì ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Whole exome sequencing is a genomic sequencing method that involves sequencing all the protein-coding regions within a genome. This laboratory technique is utilized to identify mutations that could be linked to a specific disease.

The primary offerings in the field of whole exome sequencing include systems, kits, and services. The term "system" pertains to the examination of how biological components such as molecules, cells, and organs interact and function. Various technologies, such as sequencing by synthesis, ion semiconductor sequencing, and others, are employed for applications in diagnostics, drug discovery and development, personalized medicine, agriculture, and animal research. These applications are utilized by hospitals and clinics, pharmaceutical and biotechnology companies, academic and research institutes, clinical laboratories, and other entities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The whole exome sequencing market research report is one of a series of new reports from The Business Research Company that provides whole exome sequencing market statistics, including the whole exome sequencing industry global market size, regional shares, competitors with a whole exome sequencing market share, detailed whole exome sequencing market segments, market trends, and opportunities, and any further data you may need to thrive in the whole exome sequencing industry. This whole exome sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The whole exome sequencing market size has grown rapidly in recent years. It will grow from $2.82 billion in 2024 to $3.36 billion in 2025 at a compound annual growth rate (CAGR) of 19.1%. The growth in the historic period can be attributed to genomic research advancements, precision medicine trends, rare disease diagnosis, pharmaceutical and biotech applications, declining sequencing costs.

The whole exome sequencing market size is expected to see exponential growth in the next few years. It will grow to $7.27 billion in 2029 at a compound annual growth rate (CAGR) of 21.3%. The growth in the forecast period can be attributed to expanding applications in oncology, integration in clinical diagnostics, rise in genetic testing demand, population genomics initiatives, emergence of gene therapies. Major trends in the forecast period include enhanced clinical utility and adoption, decreasing costs of sequencing, focus on data security and privacy, integration with electronic health records, advances in single-cell sequencing.

The forecast of 21.3% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. genetic diagnostics by inflating prices of next-generation sequencing platforms and bioinformatics software developed in South Korea and Israel, resulting in delayed rare disease diagnoses and higher genomic medicine program costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of HIV (human immunodeficiency virus) is anticipated to drive the growth of the whole exome sequencing market in the future. HIV is a virus that attacks the body's immune system. Whole exome sequencing provides genomic data about viruses that can be valuable for personalized treatments and vaccine development for HIV. For example, in August 2024, the Minority HIV/AIDS Fund (MHAF), a US-based government agency, reported that in 2023, around 39.9 million people worldwide were living with HIV, which includes 38.6 million adults and 1.4 million children, showing an increase compared to previous years. Consequently, the rising prevalence of HIV is fueling the growth of the whole exome sequencing market.

The rising demand for personalized medicine is also poised to drive the growth of the whole exome sequencing market. Personalized medicine tailors medical treatment to an individual's unique genetic makeup, offering more effective and precise healthcare interventions. Whole exome sequencing is integral to personalized medicine, enabling the customization of treatments based on an individual's genetic profile for precise and targeted therapies. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% (12 of them) classified as personalized medicines by the Personalized Medicine Coalition (PMC). Hence, the increasing demand for personalized medicine is a significant factor contributing to the growth of the whole exome sequencing market.

A prominent trend gaining traction in the whole exome sequencing market is the adoption of innovative diagnostic techniques. Companies within this market are actively engaged in developing new product innovations to maintain their market positions. For example, in February 2023, Illumina Inc., a biotechnology company based in the United States, introduced the NovaSeqX Plus, a state-of-the-art sequencing technology. This groundbreaking technology combines high throughput and accuracy, featuring streamlined informatics, sustainability advancements, and cost-effective sequencing. The NovaSeq X Plus systems are equipped with innovations capable of generating tens of thousands of whole genomes annually, enhancing productivity, and minimizing turnaround time.

Leading companies in the whole exome sequencing market are developing advanced next-generation sequencing (NGS) ultra-fast technology to improve the speed and accuracy of genetic analyses, facilitating quicker diagnostics and personalized treatment plans in healthcare. This NGS ultra-fast technology enhances whole exome sequencing by rapidly analyzing exonic regions, enabling the swift detection of genetic mutations that are vital for diagnosis and research. For example, in January 2023, Qiagen, a medical devices and healthcare company based in Germany, introduced the CLC Genomics Workbench Premium with Lightspeed technology. This innovation allows for efficient analysis of whole genome sequencing (WGS) and whole exome sequencing (WES) data, processing an entire genome in just 25 minutes for approximately $1 using cloud computing, while also supporting local hardware. By decreasing both time and costs, Lightspeed improves the accessibility of large-scale genetic testing in the WES market.

In January 2022, Exact Sciences, a molecular diagnostics company in the United States, acquired Prevention Genetics for a deal valued at $190 million. This strategic acquisition strengthened Exact Sciences' advanced cancer testing portfolio. Prevention Genetics, a clinical DNA testing laboratory based in the U.S., is known for providing high-quality genetic testing and services to patients and researchers.

Major companies operating in the whole exome sequencing market include Thermo Fisher Scientific Inc., Illumina Inc., Eurofins Genomics, Azenta US Inc., CD Genomics, Psomagen Inc., Agilent Technologies, BGI Genomics, F. Hoffmann-La Roche Ltd., QIAGEN Inc., Macrogen Inc., Ambry Genetics, Bio-Rad Laboratories Inc., Bioneer Corporation, Foundation Medicine Inc., KONICA MINOLTA INC., Otogenetics Corporation, Geneyx Genomex Ltd., ArcherDX Inc., Blueprint Genetics Oy, Bionano Genomics Inc., Centogene AG, Fulgent Genetics Inc., Natera Inc., GeneDx Inc., GENEWIZ Inc., Novogene Corporation, PerkinElmer Inc., Personalis Inc.

North America was the largest region in the whole exome sequencing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global whole exome sequencing market report during the forecast period. The regions covered in the whole exome sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the whole exome sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The whole exome sequencing market consists of revenues earned by entities by providing services such as exome capture, library construction, deep sequencing, raw data quality control, and bioinformatics analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The whole exome sequencing market also includes sales of instruments, comparison tools, and sequencing reagents which are used in providing whole exome sequencing services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Whole Exome Sequencing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on whole exome sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for whole exome sequencing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The whole exome sequencing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Whole Exome Sequencing Market Characteristics

3. Whole Exome Sequencing Market Trends And Strategies

4. Whole Exome Sequencing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Whole Exome Sequencing Growth Analysis And Strategic Analysis Framework

6. Whole Exome Sequencing Market Segmentation

7. Whole Exome Sequencing Market Regional And Country Analysis

8. Asia-Pacific Whole Exome Sequencing Market

9. China Whole Exome Sequencing Market

10. India Whole Exome Sequencing Market

11. Japan Whole Exome Sequencing Market

12. Australia Whole Exome Sequencing Market

13. Indonesia Whole Exome Sequencing Market

14. South Korea Whole Exome Sequencing Market

15. Western Europe Whole Exome Sequencing Market

16. UK Whole Exome Sequencing Market

17. Germany Whole Exome Sequencing Market

18. France Whole Exome Sequencing Market

19. Italy Whole Exome Sequencing Market

20. Spain Whole Exome Sequencing Market

21. Eastern Europe Whole Exome Sequencing Market

22. Russia Whole Exome Sequencing Market

23. North America Whole Exome Sequencing Market

24. USA Whole Exome Sequencing Market

25. Canada Whole Exome Sequencing Market

26. South America Whole Exome Sequencing Market

27. Brazil Whole Exome Sequencing Market

28. Middle East Whole Exome Sequencing Market

29. Africa Whole Exome Sequencing Market

30. Whole Exome Sequencing Market Competitive Landscape And Company Profiles

31. Whole Exome Sequencing Market Other Major And Innovative Companies

32. Global Whole Exome Sequencing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Whole Exome Sequencing Market

34. Recent Developments In The Whole Exome Sequencing Market

35. Whole Exome Sequencing Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â